Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for non-alcoholic fatty liver disease
RBR-48rxwbPhase 4Recruiting
- Sponsor
- Centro Educacional Hyarte
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Centro Educacional Hyarte. Started Nov 2019; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on RBR-48rxwb.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-48rxwb.